...cel (exa-cel) is a one-time nonviral gene-edited therapy approved in the United States (US) for treatment of patients ag...
...CEL). The AEL was calculated by applying a safety assessment factor of 300 to the Ni no expected sensitization induction...
...cel (tisa-cel), an autologous anti-CD19 CAR T-cell therapy, has significantly improved outcomes in pediatric, adolescent...
...Cel accelerated urethral repair within the inflammatory milieu, significantly reduced collagen deposition and ultimately...
...cel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) between May 2021 and April 2024. Outcomes were compared between b...
...cel (axi-cel) is an autologous CAR T-cell therapy, initially approved by Health Canada for adults with R/R LBCL after 2 ...
...cel (axi-cel) as second-line (2 L) treatment for large B-cell lymphoma (LBCL), results from real-world CAR T cohorts wil...
...cel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy with adaptive intra-patient ...
...cell therapies such as lisocabtagene maraleucel (liso-cel) have transformed the treatment of patients with second line p...
...CELs) development. Twenty-two studies comprising 16,585,206 participants were included. Long-term exposure to PM2.5 (HR ...
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: [email protected]
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
